1
|
Robinson I, Hochmair MJ, Schmidinger M, Absenger G, Pichler M, Nguyen VA, Richtig E, Rainer BM, Ay L, Jansen C, Pacífico C, Knabl A, Sladek B, Gasche N, Valipour A. Assessing the Performance of a Novel Stool-Based Microbiome Test That Predicts Response to First Line Immune Checkpoint Inhibitors in Multiple Cancer Types. Cancers (Basel) 2023; 15:3268. [PMID: 37444378 DOI: 10.3390/cancers15133268] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/03/2023] [Revised: 06/13/2023] [Accepted: 06/15/2023] [Indexed: 07/15/2023] Open
Abstract
The intestinal microbiome is by now an undebatable key player in the clinical outcome of ICI therapies. However, no microbiome profiling method to aid therapy decision is yet validated. We conducted a multi-centric study in patients with stage III/IV melanoma, NSCLC, or RCC receiving ICI treatment. The stool microbiome profile of 63 patients was analyzed with BiomeOne®, a microbiome-based algorithm that anticipates whether a patient will achieve clinical benefit with ICIs prior to therapy initiation. Classification of patient samples as Rs and NRs was achieved with a sensitivity of 81% and a specificity of 50% in this validation cohort. An ICI-favorable response was characterized by an intestinal microbiome rich in bacteria such as Oscillospira sp., Clostridia UCG-014, Lachnospiraceae UCG-010 sp., Prevotella copri, and a decrease in Sutterella sp., Lactobacillales, and Streptococcus sp. Patients who developed immune-related adverse events (irAEs) had an overall increased microbial diversity and richness, and a stool microbiome depleted in Agathobacter. When compared with the programmed death-ligand 1 (PD-L1) expression test in the subcohort of NSCLC patients (n = 38), BiomeOne® exhibited a numerically higher sensitivity (78.6%) in identifying responders when compared with the PD-L1 test (67.9%). This study provides an evaluation of BiomeOne®, the first microbiome-based test for prediction of ICI response, to achieve market authorization. Validation with further indications and expansion to other microbiome-based interventions will be essential to bring microbiome-based diagnostics into standard clinical practice.
Collapse
|
2
|
Weng J, Dabaja B, Das P, Gunn G, Chronowski G, Bloom E, Lee P, Koong A, Ning M, Semien K, Sanders C, Ritchey R, Nguyen K, Hoffman K, Robinson I, Kerr A, Brokaw J, Liao Z, Nguyen Q. Radiation Therapy Decision Making Process and Operations for COVID-19 Positive Patients. Int J Radiat Oncol Biol Phys 2022. [PMCID: PMC9595469 DOI: 10.1016/j.ijrobp.2022.07.1722] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Purpose/Objective(s) A challenging clinical dilemma during the COVID-19 pandemic is management of cancer patients who test positive for COVID. Given the need to balance the risk of disease progression with the risk of transmission to other patients and staff, radiation therapy for these patients requires careful consideration and modification of standard workflows. It is also critical to develop processes to mitigate radiation treatment interruption, which can affect patient outcomes. The objective of this study was to report the clinical operations and outcomes for COVID positive patients receiving radiation therapy during the pandemic at a tertiary cancer center including 2 network locations. Materials/Methods During March 2020 to March 2022, the Radiation Oncology COVID committee (RO COVID) developed an integrated process to triage patients, provide treatment recommendations, and implement infection control procedures to safely deliver radiation therapy to COVID positive patients. Policies were created for each center with multidisciplinary input from infectious disease, radiation oncology, radiation therapy, and nursing. All COVID positive patients were presented to the RO COVID group and evaluated for clinical urgency, benefit with radiation, and life expectancy. If deemed necessary, a limited planned break or hypofractionated regimen was recommended to minimize staff exposure. We conducted a retrospective review of COVID positive patients with different primary malignancies treated through the COVID positive pathway. Results A total of 68 COVID positive patients were treated with the COVID positive pathway (HN 15, Breast 9, CNS 8, GU 8, GYN, 7, Thoracic 6, GI 5, HEME 5, PED 3, SARC 2). The median age was 57.1 years (IQR 45.8-63.4) and 47% were female. There were 39 patients (57%) who were asymptomatic and were tested for routine pre-radiation screening or due to concerns of COVID exposure. Twenty-three (34%) patients were treated with palliative intent and 8 (12%) were treated for an emergent indication (i.e., spinal cord compression, bleeding). Thirteen (19%) patients were receiving radiation treatment, had a treatment break (7-21 days), and then resumed their radiation course. All treatments were successfully completed without known nosocomial spread of COVID to staff or other patients. Among this heterogenous group of patients, 58 (85%) were alive with a median follow up of 2 months (IQR 0.5-7.5). COVID infection may have contributed to 3 out of 10 deaths (4% of total cohort). The remaining deaths were due to progression of disease or other non-COVID causes. Conclusion In this study, COVID positive patients were safely treated with radiation therapy through a comprehensive decision making and clinical operations pathway taking into account evolving COVID guidelines for three different variant surges. Although limited in follow up, patient outcomes are promising with few COVID-related deaths and low overall mortality rates, even with hypofractionated regimens.
Collapse
|
3
|
Robinson I, Schmidinger M, Hochmair M, Ay L, Absenger G, Pichler M, Nguyen V, Richtig E, Rainer B, Jansen C, Sladek B, Knabl A, Gasche N, Valipour A. 117P BiomeOne: Multi-centric validation of a novel microbiome-based biomarker to predict response to cancer immunotherapy. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.149] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
4
|
Hochmair M, Absenger G, Ay L, Robinson I, Jansen C, Sladek B, Knabl A, Gasche N, Valipou A. EP16.01-015 Introducing "BiomeOne” a Microbiome-based bBiomarker to Predict Immune Checkpoint Inhibitor Response in NSCLC 1patients. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.1015] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]
|
5
|
Robinson I, Bertsch A, Leithner K, Stiegler P, Olschewski H, Hrzenjak A. Circulating microRNAs as molecular biomarkers for lung adenocarcinoma. Cancer Biomark 2022; 34:591-606. [DOI: 10.3233/cbm-210205] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/19/2022]
Abstract
BACKGROUND: The potential of microRNAs (miRNAs) as molecular tumor biomarkers for early diagnosis and prognosis in lung cancer is still unclear. OBJECTIVE: To analyze expression of miRNAs in A549 lung adenocarcinoma (LUAD) cells and in primary, non-malignant bronchial epithelial (BE) cells from healthy donors. To analyze the most prominently deregulated miRNAs in plasma samples of LUAD patients and healthy donors. MATERIALS AND METHODS: The expression of 752 miRNAs in LUAD and BE cells was assessed by RT-qPCR with mean-centering restricted normalization. The relative plasma levels of 18 miRNAs in LUAD patients and healthy donors were analyzed using RT-qPCR and normalized to miR-191-5p and miR-16-3p. Putative interactions between miRNAs and their target genes were investigated in silico. RESULTS: Out of 752 miRNAs, 37 miRNAs were significantly deregulated in A549 cells compared to BE cells. MiR-15b-3p, miR-148a-3p, miR-193b-3p, and miR-195-5p were significantly deregulated in plasma samples of LUAD patients compared to donors. The target genes of those four miRNAs are involved in essential mechanisms in cancer development and progression. CONCLUSIONS: There are substantial differences between cancer and control miRNA expression in vitro and in plasma samples of LUAD patients compared to healthy donors. Four deregulated miRNAs are promising as a diagnostic biomarker for adenocarcinoma of the lung.
Collapse
|
6
|
Garner D, Koong A, Martel M, Herman J, Ghafar R, Hines T, Das P, McAleer M, Klopp A, Nguyen Q, Zaebst D, Todd S, Allen P, Robinson I, Woodward W. Burnout among Radiation Oncology Providers and Staff in a Large Academic Center. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.843] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
|
7
|
Wallace BP, Stacy BA, Cuevas E, Holyoake C, Lara PH, Marcondes ACJ, Miller JD, Nijkamp H, Pilcher NJ, Robinson I, Rutherford N, Shigenaka G. Oil spills and sea turtles: documented effects and considerations for response and assessment efforts. ENDANGER SPECIES RES 2020. [DOI: 10.3354/esr01009] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022] Open
|
8
|
Regan L, Schneider J, Rushworth G, Brown S, Rennie J, Tait E, Cammaert L, Semple E, Clarkson M, Manson R, Gatenby A, McWilliam S, Robinson I, Al Moosawi H, Kamona A. Can we improve sepsis care, out there? Rural Remote Health 2016. [DOI: 10.22605/rrh4088] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022] Open
|
9
|
Robinson I. A diagnostic head and neck fine needle aspiration service can be provided using liquid-based cytology only. Cytopathology 2016; 28:24-30. [PMID: 27245607 DOI: 10.1111/cyt.12340] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 01/26/2016] [Indexed: 11/28/2022]
Abstract
OBJECTIVE Liquid-based cytology (LBC) has been used for non-gynaecological specimens since its introduction into routine use in cervical cytology in the mid-1990s. There are still relatively few large studies comparing performance in reporting the head and neck fine-needle aspirations (H&N FNA) processed by LBC only to conventional direct smears (CDS). METHODS This study compared 686 H&N FNAs processed by LBC only with 3719 CDS. All were taken under ultrasound (US) guidance by a small cohort of three consultant radiologists and reported by the author. RESULTS The (smaller) LBC sample was statistically representative of the larger CDS population at an alpha level of 0.05. There was no difference between CDS and LBC at a 95% confidence interval (CI) when comparing specificity and sensitivity (specificity: 94.8-96.5% versus 90.2-95.4%; sensitivity: 91.4-94.1% versus 86.8-93.4%). The inadequate rate between the two techniques was similar, 0.5-1.0% for CDS versus 0.7-2.5% for LBC. The significance difference was in the suspicious rate which was greater at 2.8-5.8% for LBC versus 1.7-2.6% for CDS. Consequently, there was a slight but non-significant difference between the two populations with respect to the overall accuracy: 93.5-95.1% for CDS versus 89.4-93.7% for LBC. CONCLUSIONS While there are morphological differences between LBC and CDS in H&N FNAs, once a degree of familiarity is achieved, the two techniques have equivalent sensitivity, specificity and inadequate rates.
Collapse
|
10
|
Glümer C, Hansen BH, AMBender AH, Andreasen KM, Robinson I, Andersen. Time trends in absolute and relative social inequality in smoking from 2007 to 2013 in the Capital Region of Denmark. Eur J Public Health 2014. [DOI: 10.1093/eurpub/cku163.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
11
|
Robinson I, Reddy AB. Molecular mechanisms of the circadian clockwork in mammals. FEBS Lett 2014; 588:2477-83. [PMID: 24911207 DOI: 10.1016/j.febslet.2014.06.005] [Citation(s) in RCA: 62] [Impact Index Per Article: 6.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/15/2014] [Revised: 05/30/2014] [Accepted: 06/02/2014] [Indexed: 01/14/2023]
Abstract
Circadian rhythms enable organisms to co-ordinate biological processes with the predictable 24 h cycle of day and night. Given that molecular clocks that coordinate such biological timing have evolved in almost all organisms, it is clear that being synchronous with the external environment confers competitive advantage. Conversely, it is apparent that being out of phase is detrimental, resulting in a number of clinical conditions, many of which are linked to metabolic dysfunction. The canonical clockwork involves a core set of genes that negatively regulate themselves through a so-called transcription translation feedback loop. However, recent studies describing evolutionarily conserved oscillations in redox reactions link circadian rhythms to metabolic processes, and in particular, redox pathways. In this review we describe the evidence for the interaction between transcriptional loops, redox and metabolism in mammals and suggest the clock may be potential target for the treatment of disease.
Collapse
|
12
|
Unterscheider J, O'Byrne J, Foran A, Robinson I, Ryan S, Devaney D, Gillick J, Malone F, Breathnach F. Prenatal identification of an accessory lower limb. Prenat Diagn 2011; 31:1203-4. [PMID: 21898470 DOI: 10.1002/pd.2846] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/21/2011] [Revised: 07/22/2011] [Accepted: 07/26/2011] [Indexed: 11/09/2022]
|
13
|
Robinson I. Coherence in crystallography for imaging materials and biology. Acta Crystallogr A 2011. [DOI: 10.1107/s0108767311099806] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
14
|
|
15
|
Gutierrez AD, de Serna DG, Robinson I, Schade DS. The response of gamma vitamin E to varying dosages of alpha vitamin E plus vitamin C. Metabolism 2009; 58:469-78. [PMID: 19303966 PMCID: PMC2688826 DOI: 10.1016/j.metabol.2008.11.003] [Citation(s) in RCA: 30] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/17/2007] [Accepted: 11/20/2008] [Indexed: 02/07/2023]
Abstract
Vitamin E has been studied extensively in the prevention of atherosclerosis. Cross-sectional population studies as well as randomized controlled intervention trials have demonstrated conflicting results. A recent meta-analysis of these trials has emphasized the ineffectiveness of vitamin E in atherosclerosis prevention, with a possibility of harm at higher dosages. However, vitamin E has several isomers, with the alpha form being available via dietary supplements and the gamma form being available via dietary foodstuffs. The gamma form of vitamin E demonstrates several superior properties (such as trapping reactive nitrogen species and detoxifying nitrogen dioxide) compared with alpha vitamin E. All clinical trials have used the alpha isomer, with little concern that this isomer of vitamin E may actually suppress the gamma isomer of vitamin E. We undertook a dose-response study in volunteers with type 2 diabetes mellitus to include all the dosages of alpha vitamin E that have been used in cardiovascular prevention trials to determine the effect of alpha vitamin E on gamma vitamin E. We also assessed the effect of alpha vitamin E on several traditional markers of atherosclerotic risk. We added vitamin C to the vitamin E because several clinical trials included this vitamin to enhance the antioxidant effects of alpha vitamin E. Volunteers received, in randomized order for a 2-week period, one of the following vitamin dosage arms: (1) no vitamins, (2) low-dose supplemental vitamins E plus C, (3) medium-dose supplemental vitamins E plus C, and (4) high-dose supplemental vitamins E plus C. Blood levels of both alpha and gamma vitamin E were measured as well as surrogate markers of oxidative stress, hypercoagulation, and inflammation during a high-fat atherogenic meal (to increase the ambient oxidative stress level during the study). The results demonstrate that alpha vitamin E levels increased in proportion to the dose administered. However, at every dose of alpha vitamin E, gamma vitamin E concentration was significantly suppressed. No beneficial changes in surrogate markers of atherosclerosis were observed, consistent with the negative results of prospective clinical trials using alpha vitamin E. Our results suggest that all prospective cardiovascular clinical trials that used vitamin E supplementation actually suppressed the beneficial antioxidant gamma isomer of vitamin E. No beneficial effects on several potential cardiovascular risk factors were observed, even when the vitamin E was supplemented with vitamin C. If a standardized preparation of gamma vitamin E (without the alpha isomer) becomes available, the effects of gamma vitamin E on atherosclerotic risk will warrant additional studies.
Collapse
|
16
|
Sillis M, Skidmore S, Mallinson H, Todd T, Coupland L, Oliver P, Robinson I, Saunders D, Hesketh L. No evidence of the Chlamydia trachomatis variant in the UK. Sex Transm Infect 2007; 83:488-9. [PMID: 17715158 PMCID: PMC2598708 DOI: 10.1136/sti.2007.027698] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/04/2022] Open
Abstract
OBJECTIVES The discovery of a variant strain of Chlamydia trachomatis (Ct) in Sweden has raised awareness of its possible undetected spread in the UK. The assays that fail to detect this variant are widely used in this country. This study aimed to determine if this variant is circulating in the UK. METHOD 1,680 genital specimens tested negative by the Roche assays were retested by Aptima Combo2. Discordant results were sequenced to check for the deletion variant. RESULTS Of 1,680 specimens tested, 29 were candidates for sequencing: 16 were negative for the variant, 11 failed to amplify, and 2 were lost. DISCUSSION No Ct deletion variants were found in the UK. If it is circulating, then the prevalence is low (0-0.77%), but even a low level cannot be ignored. The system we describe is simple and suitable for rapid response and phasing of surveillance to match an unknown level of threat if other variants emerge.
Collapse
|
17
|
Kotnis NA, Robinson I, Cozens N. Reply to Mehrotra et al: ultrasound guided thyroid cytology. Cytopathology 2007; 18:127; author reply 128-9. [PMID: 17397501 DOI: 10.1111/j.1365-2303.2007.00419.x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
18
|
Robinson I, Oh E, Drummond J, Sharma A. A novel function for syndapin at Drosophila neuromuscular junctions. Comp Biochem Physiol A Mol Integr Physiol 2007. [DOI: 10.1016/j.cbpa.2007.01.167] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
19
|
Robinson I, de Serna DG, Gutierrez A, Schade DS. Vitamin E in humans: an explanation of clinical trial failure. Endocr Pract 2006; 12:576-82. [PMID: 17002935 DOI: 10.4158/ep.12.5.576] [Citation(s) in RCA: 58] [Impact Index Per Article: 3.2] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/07/2023]
Abstract
OBJECTIVE To describe the potential benefits and hazards of vitamin E supplementation and present a rational basis for understanding the conflicting results among randomized clinical trials, epidemiologic investigations, and animal studies on the use of vitamin E to prevent atherosclerosis. METHODS We conducted a retrospective review of the pertinent literature found in PubMed from 1981 through August 2005. The published data are analyzed and summarized. RESULTS The possible factors implicated for failure of vitamin E therapy include the following: (1) the inclusion of patients without biochemical evidence of increased oxidative stress, (2) the relatively short duration of treatment, (3) the use of suboptimal dosages of vitamin E, (4) the suppression of gamma-tocopherol by alpha-tocopherol, (5) the use of vitamin E supplementation without the concurrent use of vitamin C, (6) the lack of inclusion of biochemical markers of oxidative stress and markers of vascular response, (7) the inappropriate administration of vitamins relative to meal ingestion, and (8) the poor patient compliance and the lack of monitoring of vitamin E levels. CONCLUSION Large, randomized clinical trials have not yet substantiated a beneficial effect of use of vitamin E to reduce atherosclerotic risk in humans, despite demonstration of antioxidant effects in vitro and in animals. Only in subsets of patients at high risk for atherosclerosis has a beneficial effect been suggested. Before additional large, randomized clinical trials of vitamin E are performed, the specific biologic and surrogate marker effects of vitamin E in each target population must be defined more carefully. This approach will save resources, minimize untoward side effects, and identify the patients who will benefit the most.
Collapse
|
20
|
Gutierrez AD, de Serna GD, Robinson I, Schade DS. 13 WHY VITAMIN E DOES NOT PREVENT ATHEROSCLEROSIS. J Investig Med 2006. [DOI: 10.2310/6650.2005.x0004.12] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
21
|
de Serna DG, Robinson I, Martin P, Burge M, Schade D. Comparison of Short-, Intermediate-, and Long-Acting Insulin Secretagogues in Type 2 Diabetes. J Investig Med 2006. [DOI: 10.1177/108155890605401s210] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
22
|
de Serna GD, Robinson I, Martin P, Burge MR, Schade DS. 327 COMPARISON OF SHORT-, INTERMEDIATE-, AND LONG-ACTING INSULIN SECRETAGOGUES IN TYPE 2 DIABETES. J Investig Med 2006. [DOI: 10.2310/6650.2005.x0004.326] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022]
|
23
|
Robinson I, Mrema I, Stratford I, Jaffar M. 495 The synthesis of novel 3- and 5-piperidinyl substituted indolequinone bioreductive prodrugs: mechanism of hypoxic/reductive activity. EJC Suppl 2004. [DOI: 10.1016/s1359-6349(04)80503-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/26/2022] Open
|
24
|
Sharp JF, Cozens N, Robinson I. Assessment of surgical competence in parotid surgery using a CUSUM assessment tool. CLINICAL OTOLARYNGOLOGY AND ALLIED SCIENCES 2003; 28:248-51. [PMID: 12755766 DOI: 10.1046/j.1365-2273.2003.00701.x] [Citation(s) in RCA: 7] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/20/2022]
Abstract
The introduction of professional revalidation and clinical governance imposes an increasing requirement for clinicians to provide evidence of competence. This paper introduces a CUSUM (CUmulative SUM) mathematical tool for determining trend and applies the technique to 84 consecutive parotidectomies (superficial, partial or total/near total) performed by one surgeon (J.S.). Using this operation, the paper illustrates how attainment and maintenance of competence in the field of otolaryngological surgery may be demonstrated at differing levels of rigour. The role of the CUSUM in assessing a trainee's surgical progress is also explored.
Collapse
|
25
|
Robinson I. Phasing of coherent X-ray diffraction from nanocrystals. Acta Crystallogr A 2002. [DOI: 10.1107/s010876730208515x] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|